Anti-DERL2 monoclonal antibody

Pre-made anti-DERL2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to DERL2/DERL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0684-Ab-1/ GM-Tg-hg-IP0684-Ab-2Anti-Human DERL2 monoclonal antibodyHuman
GM-Tg-rg-IP0684-Ab-1/ GM-Tg-rg-IP0684-Ab-2Anti-Rat DERL2 monoclonal antibodyRat
GM-Tg-mg-IP0684-Ab-1/ GM-Tg-mg-IP0684-Ab-2Anti-Mouse DERL2 monoclonal antibodyMouse
GM-Tg-cynog-IP0684-Ab-1/ GM-Tg-cynog-IP0684-Ab-2Anti-Cynomolgus/ Rhesus macaque DERL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0684-Ab-1/ GM-Tg-felg-IP0684-Ab-2Anti-Feline DERL2 monoclonal antibodyFeline
GM-Tg-cang-IP0684-Ab-1/ GM-Tg-cang-IP0684-Ab-2Anti-Canine DERL2 monoclonal antibodyCanine
GM-Tg-bovg-IP0684-Ab-1/ GM-Tg-bovg-IP0684-Ab-2Anti-Bovine DERL2 monoclonal antibodyBovine
GM-Tg-equg-IP0684-Ab-1/ GM-Tg-equg-IP0684-Ab-2Anti-Equine DERL2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0684-Ab-1/ GM-Tg-hg-IP0684-Ab-2; GM-Tg-rg-IP0684-Ab-1/ GM-Tg-rg-IP0684-Ab-2;
GM-Tg-mg-IP0684-Ab-1/ GM-Tg-mg-IP0684-Ab-2; GM-Tg-cynog-IP0684-Ab-1/ GM-Tg-cynog-IP0684-Ab-2;
GM-Tg-felg-IP0684-Ab-1/ GM-Tg-felg-IP0684-Ab-2; GM-Tg-cang-IP0684-Ab-1/ GM-Tg-cang-IP0684-Ab-2;
GM-Tg-bovg-IP0684-Ab-1/ GM-Tg-bovg-IP0684-Ab-2; GM-Tg-equg-IP0684-Ab-1/ GM-Tg-equg-IP0684-Ab-2
Products NameAnti-DERL2 monoclonal antibody
Formatmab
Target NameDERL2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-DERL2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0684-Ag-1Recombinant multi-species DERL2/ CGI-101/ DERtrin-2 protein


    Target information

    Target IDGM-IP0684
    Target NameDERL2
    Gene ID51009,116891,100910823,712051,606991,101090404,508465,100061027
    Gene Symbol and SynonymsCGI-101,DERL2,derlin-2,DERtrin-2,F-LAN-1,F-LANa,FLANa
    Uniprot AccessionQ9GZP9
    Uniprot Entry NameDERL2_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000072849
    Target ClassificationN/A

    The target: DERL2, gene name: DERL2, also named as CGI-101, DERtrin-2, F-LAN-1, F-LANa, FLANa, derlin-2. Proteins that are unfolded or misfolded in the endoplasmic reticulum (ER) must be refolded or degraded to maintain the homeostasis of the ER. DERL2 is involved in the degradation of misfolded glycoproteins in the ER (Oda et al., 2006 [PubMed 16449189]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.